GMAB Genmab

Price (delayed)

$22.87

Market cap

$15.14B

P/E Ratio

13.22

Dividend/share

N/A

EPS

$1.73

Enterprise value

$13.65B

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with ...

Highlights
GMAB's price to earnings (P/E) is 65% lower than its 5-year quarterly average of 37.9 and 22% lower than its last 4 quarters average of 17.0
The EPS has grown by 47% YoY
The quick ratio has dropped by 57% year-on-year but it is up by 2.1% since the previous quarter
The gross margin is down by 2.7% year-on-year

Key stats

What are the main financial stats of GMAB
Market
Shares outstanding
661.97M
Market cap
$15.14B
Enterprise value
$13.65B
Valuations
Price to earnings (P/E)
13.22
Price to book (P/B)
2.86
Price to sales (P/S)
4.81
EV/EBIT
8.56
EV/EBITDA
N/A
EV/Sales
4.34
Earnings
Revenue
$3.15B
Gross profit
$2.99B
Operating income
$1.01B
Net income
$1.11B
EBIT
$1.59B
EBITDA
N/A
Free cash flow
$1.09B
Per share
EPS
$1.73
EPS diluted
$1.72
Free cash flow per share
$1.65
Book value per share
$8
Revenue per share
$4.76
TBVPS
$6.76
Balance sheet
Total assets
$6.59B
Total liabilities
$1.29B
Debt
$129M
Equity
$5.3B
Working capital
$3.28B
Liquidity
Debt to equity
0.02
Current ratio
5.34
Quick ratio
5.33
Net debt/EBITDA
N/A
Margins
EBITDA margin
N/A
Gross margin
95.1%
Net margin
35.2%
Operating margin
32.2%
Efficiency
Return on assets
18.5%
Return on equity
23%
Return on invested capital
70.2%
Return on capital employed
27.3%
Return on sales
50.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GMAB stock price

How has the Genmab stock price performed over time
Intraday
4.91%
1 week
4.57%
1 month
10.59%
1 year
-18.15%
YTD
9.58%
QTD
10.7%

Financial performance

How have Genmab's revenue and profit performed over time
Revenue
$3.15B
Gross profit
$2.99B
Operating income
$1.01B
Net income
$1.11B
Gross margin
95.1%
Net margin
35.2%

GMAB financials

The net income has grown by 44% YoY
The operating income is up by 26% YoY and by 8% from the previous quarter
Genmab's revenue has increased by 25% YoY and by 4.5% QoQ
The company's gross profit rose by 22% YoY and by 4.1% QoQ

Price vs fundamentals

How does GMAB's price correlate with its fundamentals

GMAB Price vs fundamentals

GMAB Earnings waterfall

GMAB Price vs fair value

Growth

What is Genmab's growth rate over time

GMAB growth chart

Valuation

What is Genmab stock price valuation
P/E
13.22
P/B
2.86
P/S
4.81
EV/EBIT
8.56
EV/EBITDA
N/A
EV/Sales
4.34

Valuation vs average

Price to earnings (P/E)

GMAB's price to earnings (P/E) is 65% lower than its 5-year quarterly average of 37.9 and 22% lower than its last 4 quarters average of 17.0
The EPS has grown by 47% YoY

Price to book (P/B)

The P/B is 55% below the 5-year quarterly average of 6.3 and 8% below the last 4 quarters average of 3.1
The equity has grown by 16% YoY and by 3.1% from the previous quarter

Price to sales (P/S)

The P/S is 64% below the 5-year quarterly average of 13.3 and 8% below the last 4 quarters average of 5.2
Genmab's revenue has increased by 25% YoY and by 4.5% QoQ

Efficiency

How efficient is Genmab business performance
Genmab's return on invested capital has surged by 60% YoY and by 9% QoQ
Genmab's ROE has increased by 29% YoY but it has decreased by 3.4% from the previous quarter
The ROA has grown by 17% YoY but it has contracted by 5% from the previous quarter
The ROS has grown by 7% YoY but it has contracted by 2.3% from the previous quarter

Dividends

What is GMAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GMAB.

Financial health

How did Genmab financials performed over time

Assets vs liabilities

The total liabilities has soared by 120% YoY
The quick ratio has dropped by 57% year-on-year but it is up by 2.1% since the previous quarter

Debt vs equity

Genmab's debt is 98% less than its equity
GMAB's debt to equity is down by 33% since the previous quarter and by 33% year-on-year
The equity has grown by 16% YoY and by 3.1% from the previous quarter

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.